Table 3.
The schedule of trial enrolment and assessments
| Study period | ||||||||
| AD | Pre-D1 | OD | POD1 | POD2 | POD3 | DD | POD90 | |
| Enrolment | ||||||||
| Assessment of eligibility | · | |||||||
| Informed consent | · | |||||||
| Randomization | · | |||||||
| Outcome assessment | ||||||||
| TBL | · | · | · | · | ||||
| HBL | · | · | · | · | ||||
| DBL | · | |||||||
| ABT | · | · | · | · | · | · | ||
| Hb level | · | · | · | · | · | |||
| Coagulation parameters | · | · | · | · | · | |||
| Fibrinolysis parameters | · | · | · | · | · | |||
| Inflammatory parameters | · | · | · | · | ||||
| TEG | · | · | · | · | ||||
| Injury time | · | |||||||
| Delay of surgery | · | |||||||
| Pre-OP doses of TXA/NS | · | |||||||
| LOS | · | |||||||
| Hospitalisation expenses | · | |||||||
| DVT | · | · | · | |||||
| PE | · | · | · | |||||
| Postoperative complications | · | · | · | · | · | |||
| Adverse events | · | · | · | · | · | · | · | · |
| 90-day mortality | · | |||||||
ABT, allogeneic blood transfusion; AD, admission day; DBL, dominant blood loss; DD, discharge day; DVT, deep vein thrombosis; Hb, haemoglobin; HBL, hidden blood loss; LOS, length of stay; NS, normal saline; OD, operative day; PE, pulmonary embolism; POD1, postoperative day 1; POD2, postoperative day 2; POD3, postoperative day 3; POD90, postoperative day 90; Pre-D1, 1 day before operation; Pre-OP, preoperative; TBL, total blood loss; TEG, thromboelastography; TXA, tranexamic acid.